ASTELLAS PHARMA UNSP.ADR (YPHA) — Cash Flow Reinvestment Rate
ASTELLAS PHARMA UNSP.ADR (YPHA) has a Cash Flow Reinvestment Rate of 0.36x as of March 2025, reinvesting €70.25 Billion (capex €57.33 Billion plus investments €12.92 Billion) from operating cash flow of €194.51 Billion. See free cash flow generation of ASTELLAS PHARMA UNSP.ADR to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ASTELLAS PHARMA UNSP.ADR Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for ASTELLAS PHARMA UNSP.ADR across 4 annual periods. For the full cash flow conversion analysis, see ASTELLAS PHARMA UNSP.ADR (YPHA) cash flow conversion.
Annual Cash Flow Reinvestment Rate for ASTELLAS PHARMA UNSP.ADR (2022–2025)
Year-by-year capital reinvestment analysis for ASTELLAS PHARMA UNSP.ADR. See YPHA financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | €70.25 Billion | €194.51 Billion | €57.33 Billion | ▼ -24.5% |
| 2024 | 0.48x | €82.50 Billion | €172.47 Billion | €82.50 Billion | ▲ +55.0% |
| 2023 | 0.31x | €101.17 Billion | €327.77 Billion | €88.54 Billion | ▼ -3.1% |
| 2022 | 0.32x | €82.02 Billion | €257.44 Billion | €76.45 Billion | — |